## PROGRAM

### WEDNESDAY 7 JUNE

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00h</td>
<td><strong>Opening of the meeting</strong>&lt;br&gt;Andrea De Luca, MD, University of Siena, Italy</td>
</tr>
<tr>
<td>10.10h</td>
<td><strong>Tribute to Dr. Mark Wainberg</strong></td>
</tr>
<tr>
<td>10.30h</td>
<td>Coffee break</td>
</tr>
<tr>
<td>11.00h</td>
<td>Session 1: HIV transmission and pathogenesis</td>
</tr>
<tr>
<td>11.00h</td>
<td>Chairs: Linos Vandekerckhove and Roger Paredes</td>
</tr>
<tr>
<td>11.00h</td>
<td><strong>Advances in topical protection against HIV-1 infection</strong>&lt;br&gt;Ross Cranston, MD, FRCP, IrsiCaixa AIDS Research Institute, Spain</td>
</tr>
<tr>
<td>11.30h</td>
<td>Abstract-driven presentations:&lt;br&gt;HIV-1 B subtype genetically diverges over the years 2003-2016 and changes its pathogenic potential&lt;br&gt;Claudia Alteri #1</td>
</tr>
<tr>
<td>11.45h</td>
<td>Integrate Inhibitors based regimens limit HIV-1 tropism evolution&lt;br&gt;Rossana Scutari #2</td>
</tr>
<tr>
<td>12.00h</td>
<td>Virological failure to protease inhibitors in monotherapy is linked to the presence of signature mutations in gag without changes in HIV-1 replication&lt;br&gt;Oscar Blanch-lombarte #3</td>
</tr>
<tr>
<td>12.15h</td>
<td>Frequency of occurrence of HIV-1 superinfection in MSM&lt;br&gt;Laura Hebberecht #4</td>
</tr>
<tr>
<td>12.30h</td>
<td>Discussion</td>
</tr>
<tr>
<td>12.45h</td>
<td>Group picture</td>
</tr>
<tr>
<td>13.00h</td>
<td>Lunch</td>
</tr>
<tr>
<td>14.00h</td>
<td>Session 2: Spread of HIV drug resistance</td>
</tr>
<tr>
<td>14.00h</td>
<td>Chairs: Annemarie Wensing and Jan Albert</td>
</tr>
<tr>
<td>14.00h</td>
<td><strong>The new WHO global action plan 2016-2021</strong>&lt;br&gt;Silvia Bertagnolio, MD, WHO, Switzerland</td>
</tr>
<tr>
<td>14.30h</td>
<td>Abstract-driven presentations:&lt;br&gt;Molecular epidemiology and patterns of transmitted drug resistance in HIV-1 infected African migrants followed-up in Portugal&lt;br&gt;Ana Abecasis #5</td>
</tr>
<tr>
<td>14.45h</td>
<td>High levels of resistance among HIV-1 treatment naive patients in Greece, a nationwide study: Evidence for country and regional level transmission networks&lt;br&gt;Dimitrios Paraskevis #6</td>
</tr>
<tr>
<td>15.00h</td>
<td>Trends for transmitted drug resistance and prevalence of non-B subtypes in recent HIV infections – results from the national molecular surveillance, Germany 2013 - June 2016&lt;br&gt;Andrea Hauser #7</td>
</tr>
</tbody>
</table>
15.15h Epidemiological study of Doravirine associated resistance mutations in HIV-1-infected treatment-naïve patients from two large databases in France and Italy

Anne - Geneviève Marcelin #8

15.30h Discussion

15.45h Coffee break

Session 3: Hepatitis B

Chairs: Anna Maria Geretti and Jens Verheyen

16.15h New therapeutic strategies
Pietro Lampertico, MD, PhD, University of Milan, Italy

16.45h Risk and management of HBV reactivation
Caroline den Hoed, MD, PhD, Erasmus MC, the Netherlands

Abstract-driven presentations:

17.15h The extent of genetic variability in HBsAg C-terminus profoundly affects HBsAg levels in eAg-negative chronic HBV genotype D infection
Arianna Battisti #9

17.30h Positively charged mutations in HBsAg C-terminus are tightly correlated with HBV-induced hepatocellular carcinoma by altering the structural folding of this domain
Romina Salpini #10

17.45h Discussion

18.00h Welcome reception and poster viewing session 1 (posters 22 to 49)

THURSDAY 8 JUNE

Session 4: Clinical Management of HIV infected patients

Chairs: Andrea De Luca and Gary Rubin

08.30h Remaining and emerging challenges for HIV clinical management
Roger Paredes, MD, PhD, IrsiCaixa AIDS Research Institute, Spain

Abstract-driven presentations:

09.00h Analysis of the association of HIV-1 low level viremia and treatment failure of antiretroviral therapy
Nadine Lübke #11

09.15h Effectiveness of protease inhibitor-based second-line antiretroviral therapy for the treatment of HIV-1 infection in sub-Saharan Africa
Anna - Maria Geretti #12

09.30h Impact of M184V resistance mutation on virological efficacy of lamivudine-based maintenance dual therapies: an Italian ARCA cohort study
Roberta Gagliardini #13

09.45h A low genetic barrier and reactivation of pre-existing proviruses harboring a single INSTI-RAM explains virological failure during dolutegravir maintenance monotherapy.
Jeroen van Kampen #14
10.00h  Sensitivity of a novel translocation defective reverse transcriptase inhibitor, EFDa in comparison to second generation NNRTIs, Etravirine and Rilpivirine on diverse HIV-1 subtypes

Ujjwal Neogi  #15

10.15h  Discussion

10.30h  Coffee break and poster viewing session 2 (posters 50 to 80)

Session 5: HIV Therapy: What is the magic number?

Chairs: Charles Boucher and Jonathan Schapiro

11.30  The virologist’s perspective
Anne-Geneviève Marcelin, PharmD, PhD. Pierre et Marie Curie University, France

11.50  The clinician’s perspective
Andrea De Luca, MD, University of Siena, Italy

12.10  The pharmacologist’s perspective
Giovanni Di Perri, MD, PhD, University of Turin, Italy

12.30  Discussion

13.00h  Lunch

12TH INTERNATIONAL WORKSHOP ON HEPATITIS C: RESISTANCE AND NEW COMPOUNDS

Session 1:

Chairs: Stéphane Chevaliez

14.00h  Acute hepatitis C : treatment as prevention
Charles Boucher, MD, PhD, Erasmus MC, the Netherlands

14.30h  Clinical relevance of hepatitis C resistance
Francesca Ceccherini - Silberstein, PhD, University of Rome ‘Tor Vergata’, Italy

Abstract-driven presentations:

15.00 Resistance-associated and fitness-associated substitutions on NS3, NS5A and NS5B genes in real-life HCV positive patient failed to 3D therapy.
Nadia Marasco  #16

15.15 Real-life efficacy of HCV-retreatment after DAA-failure: the role of NS5A-resistance
Valeria Cento  #17

15.30 Retreatment of DAA failures with approved regimens and resistance information in a real life setting: data form the HepcResp Gehep004 cohort
Federico García  #18

15.45h  Discussion

16.00h  Coffee break
### Session 2:

**Chairs:** Anita Howe and Francesca Ceccherini

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.30h</td>
<td><strong>The German HCV drug resistance (RAS) database</strong></td>
<td>Johannes Vermehren, MD, University Hospital Frankfurt, Germany</td>
</tr>
<tr>
<td>17.00h</td>
<td><strong>The European Hepcare project</strong></td>
<td>Valeria Cento, PhD, University of Rome “Tor Vergata”, Italy</td>
</tr>
</tbody>
</table>

**Abstract-driven presentation:**

17.15h Clinical relevance of accurate HCV genotype and subtype assignment by HCV Sanger and next generation sequencing in the era of new direct acting antiviral agents

Marianna Aragri #19

17.30h **Round table discussion: Future of resistance data repositories: European and Global initiative**

*Panel members: Anita Howe, Federico Garcia and Francesca Ceccherini*

18.00h End of program Day 2

19.30h Networking dinner - Caffè Ciampini Restaurant [pre-registration required]

Departure at 19.10 from Roma Eventi - Fontana di Trevi

### FRIDAY 9 JUNE

**Session 7: HIV multidrug resistance: challenges and strategies**

**Chair:** Carlo Federico Perno and Clive Loveday

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30h</td>
<td><strong>The clinical use of HIV-DNA quantity and resistance testing</strong></td>
<td>Maurizio Zazzi, MSc, University of Siena, Italy</td>
</tr>
</tbody>
</table>

**Abstract-driven presentations:**

09.00h HIV-1 drug resistance testing using Nanopore technology – a long-range low error sequencing approach using rolling circle amplification

Martin Däumer #20

09.15h Next generation sequencing in reverse transcriptase and protease of HIV-1 helps to discriminate recent from chronically infected newly diagnosed patients

Jose Angel Fernandez-Caballero Rico #21

09.30h **Round table discussion: Patients with multiresistant virus: A limited number, but a remarkable deal**

*Introduction by Maria Santoro, PhD, University of Rome “Tor Vergata”, Italy*

10.15h **Discussion**

10.30h Coffee break and poster viewing session 3 [posters 81 to 110]
Session 8: New frontiers in HIV science

Chairs: Charles Boucher and Andrea De Luca

11.30h Update of cure strategies
Monique Nijhuis, PhD, University Medical Centre Utrecht, the Netherlands

12.00h Is HIV management moving towards personalized medicine?
Carlo Federico Perno, MD, PhD, University of Rome Tor Vergata, Italy

12.30h Long-acting injectables
Ian McGowan, MB, ChB, DPhil, MD, FRCP, University of Pittsburg, USA

13.00h Discussion

13.30h Closing remarks